The kick-off of the flu vaccination is given on Tuesday, October 17 in France.
The Biogaran laboratory, a subsidiary of Servier, intends to question the archdominance of Sanofi, which holds more than 50% of the French market, and its rival Viatris (ex-Mylan).
Biogaran has sealed an agreement with GSK to distribute its vaccine in France.
Will GSK's second attempt be the right one?
The British had left the French market four years ago, having been unable to find a place there.
He had suffered from not having a commercial team to promote his vaccine in pharmacies.
He is now betting on Biogaran, the French number one in generics.
“
We are aiming for a third of the market within five years,
” says Jérôme Wirotius, Managing Director of Biogaran.
A market that we see growing by then to 18 million doses (against 13 to 15 million on average currently).
»
Read alsoIncreased competition over the flu vaccine
For Biogaran, the flu vaccine is also a way to conquer more pharmacies.
Whether…
This article is for subscribers only.
You have 76% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login